Futura Medical plc is a pharmaceutical group that develops innovative products for the consumer healthcare market.
The Company's shares are quoted on the AIM market of the London Stock Exchange.
Futura Medical is committed to developing products with the potential for a significant return on the costs of development.
We are developing a portfolio of products in sexual healthcare and pain relief management and are evaluating further therapeutic opportunities as potential additions to the growing pipeline. We have currently five main products in development for sexual healthcare and pain relief management: CSD500, MED2002, PET500, TPR100 and RAD100.
SSL International plc ("SSL") has global distribution rights for our condom product CSD500 which will be our first product to market. We also have with SSL a global development and licensing agreement for MED2002, our erectile dysfunction gel. In addition, we are in non-exclusive discussions for the distribution rights to our product for topical pain relief TPR100.
We are actively working on the next generation of product opportunities, as well as evaluating the use of our proprietary delivery system DermaSys® in a range of other compounds.
